Allen C. L. Email & Phone Number
@astatechinc.com
3 phones found area 215
LinkedIn matched
Who is Allen C. L.? Overview
A concise factual answer block for searchers comparing this professional profile.
Allen C. L. is listed as Vice President, Business Development at PharmaBlock Sciences (Group) at PharmaBlock Group, based in New Hope, Pennsylvania, United States. AeroLeads shows a work email signal at astatechinc.com, phone signal with area code 215, and a matched LinkedIn profile for Allen C. L..
Allen C. L. previously worked as Vice President of Business Development at Pharmablock Group and Executive Director, Business Development & Markeing at Pharmablock Group. Allen C. L. holds Ms, Organic Chemistry from Auburn University.
Email format at PharmaBlock Group
This section adds company-level context without repeating Allen C. L.'s masked contact details.
AeroLeads found 1 current-domain work email signal for Allen C. L.. Compare company email patterns before reaching out.
About Allen C. L.
Allen C. L. is a Vice President, Business Development at PharmaBlock Sciences (Group) at PharmaBlock Group. He possess expertise in process chemistry, project management, product development, business development, intellectual property and 9 more skills.
Listed skills include Process Chemistry, Project Management, Product Development, Business Development, and 10 others.
Allen C. L.'s current company
Company context helps verify the profile and gives searchers a useful next step.
Allen C. L. work experience
A career timeline built from the work history available for this profile.
Executive Director, Business Development & Markeing
Sr. Director, Business Development
PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; and manufacturing of key intermediates and APIs.Founded in 2006 in Nanjing, PharmaBlock is committed to helping its worldwide customers maximize the discovery and development efficiency of making next generations of medicines. It has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Continuing on that success and to provide a more comprehensive and long-term service to valued customers, the company established BTC Pharmaceutical Co., Ltd. in Nantong, Jiangsu province as its pilot plant site in 2015, and acquired Shandong Diai Biotechnology Co., Ltd. in Dezhou, Shandong province as its manufacturing site in 2016. PharmaBlock has partnered with over 80% of the top 20 pharmaceutical companies, and hundreds of small to medium-sized biotechs around the world. In 2011, the company opened a new facility in the San Francisco Bay area ( Pharmablock USA Inc.), aiming for more efficient and timely services to local customers in the United States and EuropeCurrently Pharmablock has 2600 employees at 6 sites in China and US.
Vice President Of Business Development
Current
Co Founder
CurrentNiRACLE is an innovative Contract Research Organization (CRO), providing Near Infrared (NIR) method development, Process Analytical Technology (PAT), Quality by Design (QbD), and process validation support to the pharmaceutical industry. NiRACLE has pioneered the Supervised Principal Component Analysis (SPCA) technology, a novel multivariate data analysis approach that can be used in NIR-related quantitative analysis (US Patent No. US2011/ 0216313 A1).NiRACLE’s services let the clients build high degree of assurance in their products as well as manufacturing processes through historical data analysis, design of experiments (DOE), and multivariate modeling. NiRACLE’s unique ways of combining DOE with both statistical and chemometric modeling speed up product and process development and lower R&D costs.
Vp, Technology And Business Development
Sr. Director, Technology And Business Development
In this position I am responsible for company's marketing and sales department, including identify new business opportunities, discover new leads, networking, building client relationship, project management, client communication at routine bases, negotiating business terms with customers/ distributors and suppliers, internal collaboration cross functions to achieve common business goals, managing raw material supply chain and identify new external partners. The effort results AstaTech bulk chemical sale increasing year after year since 2010 in an otherwise overall slow industrial environment.
Director Of Technology And Business Development
Keystone Business Park2525 Pearl Buck RoadBristol, PA 19007 cluo@astatechinc.comTel : 215-785-3197 X 313Fax: 215-785-2656
Founder
NPE is an energy saving firm focusing on coal fire power plants modification. Promoting world leading combustion technology to improve coal efficiency and air quality.
Sr Asso. Scientist; Asso Scientist / Medchem
Early drug discovery focused on selectivity, bioavailability and toxicity profile: Synthesis of novel diarylacetylene piperidinyl amides as Neurokinin 1 receptor modulators. Key role in discovering the compound which advanced into preclinical development.Synthesis of novel 2-aminoquinazolines, 2-aminoquinolines and 2-aminopyridopyrimidines as inhibitors of beta-Site APP Cleaving Enzyme for treating Alzheimer's Disease. Improved potency to single digit nM Ki as well as selectivity and ADME properties. Discover a new synthetic route to prepare the cis-isomer analog of JNJ XXXXX816. Synthesis of first in class Medium Acyl-CoA Synthetase 2 (MACS2) inhibitors for diabetes and obesity. Discovered novel 2a/2b dual and 2b selective inhibitors. Improved solubility and CACO properties to address bioavailability issues.Preparation of novel amino-phenylacetic acids as gama-secretase modulators (GSM) for treating Alzheimer's Disease. Most potent analogs had IC50s below 100 nM. Large scale chiral synthesis of a tetrahydronaphthalene, an inhibitor of beta-amyloid1-42 aggregation. Preparation of novel (arylsulfonamidophenyl) pyrazolamines as Neuropeptide Y5 modulators for the treatment of obesity.
Process Chemist
Process development of HIV-1 reverse transcriptase inhibitor(DMP266), later become Sustiva™ (Efavirenz).
Research Associate
Early Drug discovery, 2-adrenergic receptor subtype selective agonists as novel pain killer
Allen C. L. education
-
Auburn University
Frequently asked questions about Allen C. L.
Quick answers generated from the profile data available on this page.
What company does Allen C. L. work for?
Allen C. L. works for PharmaBlock Group.
What is Allen C. L.'s role at PharmaBlock Group?
Allen C. L. is listed as Vice President, Business Development at PharmaBlock Sciences (Group) at PharmaBlock Group.
What is Allen C. L.'s email address?
AeroLeads has found 1 work email signal at @astatechinc.com for Allen C. L. at PharmaBlock Group.
What is Allen C. L.'s phone number?
AeroLeads has found 3 phone signal(s) with area code 215 for Allen C. L. at PharmaBlock Group.
Where is Allen C. L. based?
Allen C. L. is based in New Hope, Pennsylvania, United States while working with PharmaBlock Group.
What companies has Allen C. L. worked for?
Allen C. L. has worked for Pharmablock Group, Pharmablock (Usa), Inc., Niracle, Astatech, Inc., and North Point Energy Llc.
How can I contact Allen C. L.?
You can use AeroLeads to view verified contact signals for Allen C. L. at PharmaBlock Group, including work email, phone, and LinkedIn data when available.
What schools did Allen C. L. attend?
Allen C. L. holds Ms, Organic Chemistry from Auburn University.
What skills is Allen C. L. known for?
Allen C. L. is listed with skills including Process Chemistry, Project Management, Product Development, Business Development, Intellectual Property, Drug Development, Mass Spectrometry, and Customer Service.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial